NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives it... NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States. Show more
PANOVA-3 a atteint son objectif principal avec une amélioration statistiquement importante de la survie globale des patients atteints d'un adénocarcinome pancréatique non résécable et localement...
PANOVA-3試験でゲムシタビンおよびnab-パクリタキセルと併用したTTフィールドを一次治療として用いた切除不能な局所進行膵腺がん患者の全生存期間が統計的に有意に改善、主要評価項目を達成 アメリカ、EU、日本...
PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated in the...
PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated in the first...
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences: Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024, in Coral Gables...
Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of...
New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.235 | 0.771376989989 | 30.465 | 31.99 | 29.81 | 850116 | 30.97643141 | CS |
4 | 10.84 | 54.5820745217 | 19.86 | 34.13 | 19.575 | 1927943 | 29.96425812 | CS |
12 | 15.65 | 103.986710963 | 15.05 | 34.13 | 14.17 | 1368756 | 22.97595724 | CS |
26 | 12.66 | 70.177383592 | 18.04 | 34.13 | 14.17 | 1320068 | 20.37748223 | CS |
52 | 17 | 124.087591241 | 13.7 | 34.13 | 11.7 | 1326261 | 18.28459878 | CS |
156 | -53.3 | -63.4523809524 | 84 | 120.03 | 10.87 | 1097074 | 38.16840661 | CS |
260 | -56.85 | -64.9343232439 | 87.55 | 232.76 | 10.87 | 1010160 | 67.02949891 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales